Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study.
The objective of this prospective, randomised study was to compare the efficacy, safety and tolerability of vaginal micronised progesterone with oral dydrogesterone as luteal phase support after in-vitro fertilisation (IVF). A total of 430 women underwent IVF/intracytoplasmic sperm injection (ICSI) treatment. Long protocol gonadotropin releasing hormone analogue down-regulation was followed by gonadotropin stimulation. Human chorionic gonadotropin was given when two or more follicles reached > or = 17 mm. After 36 h, oocytes were retrieved and IVF was performed. Embryo transfer was done at the 4-8 cell embryo stage. Luteal support was initiated from the day of embryo transfer and continued for up to 14 days. Patients were randomised to luteal supplementation with either intravaginal micronised progesterone 200 mg three times daily (n=351) or oral dydrogesterone 10 mg twice daily (n=79). In cases of a positive pregnancy test, luteal support was continued for 12 weeks. Both dydrogesterone and micronised progesterone were associated with similar rates of successful pregnancies. Vaginal discharge or irritation were reported by 10.5% of patients given micronised progesterone. Significantly (p<0.05), more patients given dydrogesterone than micronised progesterone were satisfied with the tolerability of their treatment. There were no differences between the treatments with regard to liver function tests.
Chakravarty
Baidya Nath
BN
Department of ART, Institute of Reproductive Medicine, Calcutta 700106, West Bengal, India. bnc@irmbnc.org
Shirazee
Hasibul Hasan
HH
Dam
Purvita
P
Goswami
Sourendra Kanta
SK
Chatterjee
Ratna
R
Ghosh
Sanghamitra
S
D000282:Administration, Intravaginal; D000284:Administration, Oral; D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D004394:Dydrogesterone / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects*; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D011374:Progesterone / Q000008:administration & dosage* / Q000494:pharmacology; D011446:Prospective Studies; D027724:Reproductive Techniques, Assisted; D020554:Sperm Injections, Intracytoplasmic / Q000187:drug effects
D006063:Chorionic Gonadotropin; D011374:Progesterone; D004394:Dydrogesterone